X @Bloomberg
Bloomberg·2025-12-15 08:00
Sanofi’s experimental MS drug has been hit with two setbacks: a regulatory delay in the US as well as a failure in a late-stage clinical trial https://t.co/KUsi2lgQit ...
Sanofi’s experimental MS drug has been hit with two setbacks: a regulatory delay in the US as well as a failure in a late-stage clinical trial https://t.co/KUsi2lgQit ...